[FLDM] Fluidigm Corporation

Overview

Type of security: Stock

Sector: Capital Goods

Industry: Biotechnology: Laboratory Analytical Instruments

Market Capitalization: 282.85 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 7.48 Change: 0.29 (4.03%)
Ext. hours: Change: 0 (0%)

chart FLDM

Refresh chart

Strongest Trends Summary For FLDM

FLDM is in the medium-term down -41% in 1 month. In the long-term up 28% in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Fluidigm Corporation develops, manufactures, and sells microfluidic systems worldwide. It offers BioMark HD System that performs high-throughput and single-cell targeted gene expression analysis, single nucleotide polymorphism (SNP) genotyping, and digital polymerase chain reaction (PCR) using Fluidigm DELTAgene and SNPtype assays, other chemistries, and Fluidigm Dynamic Array and Digital Array integrated fluidic circuits (IFCs). The company also provides C1 Single-Cell Auto Prep System, which enables the isolation, processing, and profiling of individual cells for genomic analysis for applications comprising single-cell targeted gene expression, single-cell micro ribonucleic acid (RNA) analysis, single-cell messenger RNA analysis, and single-cell targeted DNA sequencing using the company?s C1 Single-Cell Auto Prep Array IFCs and C1 reagent kit. In addition, it offers EP1 System, which performs SNP genotyping using Fluidigm SNPtype assays or TagMan assays, as well as end-point digital PCR using TaqMan assays,

Fundamental Ratios
Shares Outstanding29.01 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -3.18% Sales Growth - Q/Q-20.19% P/E
P/E To EPS Growth P/S2.41 P/BV1.99 Price/Cash Per Share2.43
Price/Free Cash Flow-9.42 ROA-13.5% ROE-37.45% ROI-15.7%
Current Ratio6.23 Quick Ratio5.53 Long Term Debt/Equity1.5 Debt Ratio0.17
Gross Margin61.87% Operating Margin-41.94% Net Profit Margin-45.42% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities3.73 M Cash From Investing Activities10.07 M Cash From Operating Activities-9.8 M Gross Profit16.08 M
Net Profit-15.93 M Operating Profit-14 M Total Assets395.03 M Total Current Assets155.23 M
Total Current Liabilities24.9 M Total Debt195.51 M Total Liabilities252.58 M Total Revenue26.73 M
Technical Data
High 52 week14.36 Low 52 week6.04 Last close6.98 Last change5.76%
RSI20.39 Average true range0.86 Beta1.19 Volume281.03 K
Simple moving average 20 days-31.91% Simple moving average 50 days-39.09% Simple moving average 200 days-34.2%
Performance Data
Performance Week-13.29% Performance Month-36.89% Performance Quart-42.88% Performance Half-25.35%
Performance Year3.71% Performance Year-to-date-19.03% Volatility daily9.62% Volatility weekly21.52%
Volatility monthly44.09% Volatility yearly152.75% Relative Volume318.24% Average Volume953.85 K
New High New Low

News

2019-09-18 08:30:00 | CyTOF Inventors Receive Prestigious Science and Technology Award from the Human Proteome Organization HUPO

2019-09-10 07:30:00 | Fluidigm Files Patent Infringement Suit Against IONpath

2019-09-09 08:30:00 | Fluidigm Revolutionizes Next-Generation Sequencing RNA Library Preparation with Microfluidic Automation

2019-09-04 08:30:00 | Fluidigm Launches Imaging Mass Cytometry Immuno-Oncology Panel Kits and Advanced CyTOF Software at the 2019 World Molecular Imaging Congress WMIC

2019-08-27 08:30:00 | Fluidigm and the Icahn School of Medicine at Mount Sinai Collaborate on Landmark Single-Cell Study of the Human Epigenome

2019-08-21 07:48:43 | Have Insiders Been Buying Fluidigm Corporation NASDAQ:FLDM Shares This Year?

2019-08-20 16:05:00 | Fluidigm to Participate in Upcoming Health Care Investor Conferences

2019-08-05 16:10:39 | Fluidigm is Running in Place, but Expects to Break Out in 2020

2019-08-02 13:15:00 | Here's Why Fluidigm Is Getting Crushed Today

2019-08-02 09:24:23 | Fluidigm FLDM Q2 2019 Earnings Call Transcript

2019-08-02 03:30:55 | Edited Transcript of FLDM earnings conference call or presentation 1-Aug-19 9:00pm GMT

2019-08-02 00:41:18 | CORRECTING and REPLACING - Fluidigm Announces Second Quarter 2019 Financial Results

2019-08-01 16:05:00 | Fluidigm Announces Second Quarter 2019 Financial Results

2019-08-01 16:01:00 | Jonathan Day Named VP, Commercial Operations, Americas

2019-08-01 08:30:00 | Fluidigm to Automate RNA Sequencing Library Preparation Using Microfluidics Technology

2019-07-30 08:30:00 | Fluidigm Announces 3rd Annual Imaging Mass Cytometry User Group Meeting

2019-07-25 10:33:02 | Fluidigm FLDM May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

2019-07-25 08:30:00 | Bill W. Colston Named to Fluidigm Board of Directors

2019-07-08 07:45:48 | Update: Fluidigm NASDAQ:FLDM Stock Gained 90% In The Last Year

2019-07-03 13:05:00 | Fluidigm Announces Conference Call and Webcast of Second Quarter 2019 Financial Results

2019-06-20 08:30:00 | Fluidigm Highlights New Advancements in Deep Cellular Profiling from Circulation to Tissue at CYTO 2019

2019-06-19 08:30:00 | Fluidigm Introduces Three Imaging Mass Cytometry Panel Kits and Advanced CyTOF Software to Accelerate Immuno-Oncology Research

2019-06-17 08:30:00 | Fluidigm Scales Highly Multiplexed Cell Analysis with Introduction of Seven New Metal Markers

2019-06-04 08:30:00 | Oncology Researcher Andrew Quong Joins Fluidigm as Chief Science Officer

2019-05-31 17:37:36 | Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-05-29 08:45:00 | Fluidigm Introduces Advanta RNA Fusions NGS Library Prep Assay to Accelerate Translational and Clinical Cancer Research

2019-05-29 08:30:00 | Fluidigm Introduces Automated Advanta Solid Tumor NGS Library Prep Assay Using Microfluidics Technology

2019-05-12 21:47:23 | Hedge Funds Have Never Been This Bullish On Fluidigm Corporation FLDM

2019-05-10 16:05:00 | Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-05-09 08:30:00 | Fluidigm to Participate in Upcoming Health Care Investor Conferences

2019-05-06 20:00:00 | Fluidigm Delivers Growth Where It Matters Most in Q1 2019

2019-05-04 09:15:01 | Stocks Soar on Strong Jobs Report; NASDAQ at New High

2019-05-03 14:38:00 | Here's Why Fluidigm Shares Fell as Much as 14.4% Today

2019-05-03 01:24:07 | Fluidigm FLDM Q1 2019 Earnings Call Transcript

2019-05-03 01:07:07 | Edited Transcript of FLDM earnings conference call or presentation 2-May-19 9:00pm GMT

2019-05-02 20:35:12 | Fluidigm FLDM Reports Q1 Loss, Tops Revenue Estimates

2019-05-02 19:25:40 | Fluidigm: 1Q Earnings Snapshot

2019-05-02 16:05:00 | Fluidigm Announces First Quarter 2019 Financial Results

2019-05-02 16:02:00 | Leading Cancer Center in Japan Selects Hyperion Imaging System to Expand Immuno-Oncology Research Studies in Colorectal Cancer

2019-05-01 10:26:02 | Masimo Gets CE Mark for ANI Module, Enhances Root Platform

2019-04-30 09:00:00 | Fluidigm Announces 8th Annual Mass Cytometry Summit

2019-04-29 09:41:01 | Can Mass Cytometry Drive Fluidigm's FLDM Q1 Earnings?

2019-04-25 10:34:02 | Fluidigm FLDM May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

2019-04-23 06:00:00 | What to Watch When Fluidigm Reports Q1 Earnings

2019-04-08 15:55:02 | How Should Investors Feel About Fluidigm Corporation's NASDAQ:FLDM CEO Pay?

2019-04-08 14:49:00 | 3 Stocks to Hold for the Next 20 Years

2019-04-05 09:40:01 | Here's Why You Should Invest in DENTSPLY XRAY Stock Now

2019-04-04 16:05:00 | Fluidigm Announces Conference Call and Webcast of First Quarter 2019 Financial Results

2019-04-03 10:32:02 | AngioDynamics' ANGO Q3 Earnings & Revenues Lag Estimates

2019-04-02 10:20:02 | AngioDynamics Gets FDA Nod to Begin NanoKnife DIRECT Study